Oasmia Pharmaceutical (STO: OSM) on Tuesday reported positive results for its cancer drug Paclical (paclitaxel) following a head-to-head comparison study with Celgene's (Nasdaq: CELG) Abraxane (paclitaxel).
The Sweden-based pharmaceutical company in a statement said the study was conducted in women with metastatic breast cancer. News of the positive trial outcome pushed Oasmia's share up 5.1% to 18.70 Swedish kronor.
Margareta Eriksson, vice president of clinical development at Oasmia Pharmaceutical, said: "Paclical enables higher doses, shortens infusion time, eliminates the need for pre-medication and improves the safety profile for patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze